RNA 치료제 및 RNA 백신 시장 : 모달리티별, 분자 유형별, 치료 영역별, 투여 경로별, 주요 지역별, 주요 기업별 - 업계 동향과 세계 예측(- 2035년)

RNA Therapeutics and RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions and Leading Players: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 RNA 치료제 및 RNA 백신 시장 규모는 2035년까지 68%의 연평균 복합 성장률(CAGR)로 확대되어 9억 4,000만 달러 규모로 성장할 것으로 예상됩니다.

인체의 단백질 생산과 유전자 기능 조절에 있어 RNA의 중요한 역할로 인해 RNA는 잠재적인 치료 수단으로 연구되고 있습니다. 연구자들은 이전에는 치료가 불가능하다고 여겨졌던 질병을 특이적으로 표적화하여 치료할 수 있다는 점에서 RNA 기반 의약품과 관련된 큰 잠재력을 발견하고 있습니다. 그러나 이러한 분자는 매우 불안정하기 때문에 치료법으로 적용하기에는 큰 저항이 있습니다. 최근 첨단 기술과 플랫폼의 등장으로 업계 관계자들의 관심은 안정성이 높고 비교적 낮은 용량으로 효과가 지속될 수 있는 개량형 RNA 기반 치료제로 옮겨가고 있습니다. 이러한 개량형 RNA 기반 치료제는 차세대 치료제로 불리며, 향후 10년간 빠르게 발전하여 차세대 주요 치료 접근법이 될 것으로 예상되며, RNA 치료제 및 백신 시장은 연구개발 노력, 투자 활동의 활성화, 유력 기업의 진입 증가에 힘입어 향후 큰 성장이 예상됩니다.

100개 이상의 차세대 RNA 치료제와 백신이 개발되어 다양한 치료 적응증에 대한 저용량 치료제를 제공합니다. 차세대 치료제의 75%는 주로 감염성 질환을 타겟으로 하는 신약개발 및 전임상 단계에 있으며, 업계는 차세대 치료제 포트폴리오를 적극적으로 추진하고 있습니다.

이러한 기술의 대부분은 세포 내 특정 부위에 표적 치료제의 전달을 촉진하는 것으로, RNA 치료제와 백신에 초점을 맞춘 대부분의 임상시험이 2022년에 등록되었습니다. 이들 임상시험의 70% 이상이 다양한 장소에서 완료되었거나 현재 환자를 모집하고 있습니다. 차세대 RNA 치료제 및 백신 관련 특허는 이 분야에서 창출된 지적 재산을 보호하기 위해 업계 내/외부 기업별로 1,170건에 가까운 특허가 출원/출원되었습니다. 이 시장에서 체결된 거래의 약 70%는 saRNA 치료제/백신 임상연구에 초점을 맞추고 있으며, 그 중 60% 이상의 파트너십이 감염성 질환 치료를 위해 체결되고 있습니다. 최근 몇 년동안 진행된 파트너십 및 자금 지원을 포함하여 차세대 RNA 치료제/백신에 초점을 맞춘 이니셔티브의 수가 증가함에 따라 주요 제약사들의 관심이 높아진 것을 알 수 있습니다. 차세대 RNA 치료제/백신 관련 시장 기회는 2026년부터 2035년까지 연평균 50% 이상 성장할 것으로 예상됩니다.

세계의 RNA 치료제 및 RNA 백신 시장에 대해 조사했으며, 시장 개요와 함께 양식별/분자 유형별/치료 영역별/투여 경로별/주요 지역별, 주요 기업별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 시장 구도

제7장 기술 상황

제8장 약제 개요

제9장 임상시험 분석

제10장 특허 분석

제11장 파트너십 및 협업

제12장 자금조달과 투자 분석

제13장 대형 제약회사의 이니셔티브

제14장 RNA 치료제 및 RNA 백신 시장 전체(-2035년)

제15장 RNA 치료제 및 RNA 백신 시장 전체, 모달리티별

제16장 RNA 치료제 및 RNA 백신 시장 전체, 분자 유형별

제17장 RNA 치료제 및 RNA 백신 시장 전체, 치료 영역별

제18장 RNA 치료제 및 RNA 백신 시장 전체, 투여 경로별

제19장 RNA 치료제 및 RNA 백신 시장 전체, 주요 지역별

제20장 RNA 치료제 및 RNA 백신 시장 전체, 주요 기업별

제21장 결론

제22장 부록 1 : 표 형식 데이터

제23장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: OVERVIEW

As per Roots Analysis, the global RNA therapeutics market and RNA vaccines market is estimated to grow to USD 940 million by 2035, at a CAGR of 68% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Modality

• RNA Therapeutics
• RNA Vaccines

Type of Molecule

• Replicating RNA
• Self Amplifying RNA
• Self Activating RNA
• Self Amplifying mRNA
• Transfer RNA

Therapeutic Areas

• Infectious Diseases
• Oncological Disorders

Route of Administration

• Intradermal
• Intramuscular
• Intravenous

Key Geographical Regions

• North America
• Asia-Pacific

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: GROWTH AND TRENDS

Given the critical role it plays in producing proteins and regulating gene function in the human body, RNA is being investigated as a potential therapeutic modality. Researchers are realizing the vast potential associated with RNA-based drugs, given their ability to specifically target and treat diseases that earlier deemed untreatable. However, the highly unstable nature of such molecules offers significant resistance to their applicability as treatment options. In recent years, the advent of advanced technologies and platforms has escalated the interest of industry stakeholders towards enhanced and modified RNA-based therapies, that are believed to be highly stable and have an extended impact at relatively low doses. This class of modified RNA-based therapies is termed as next generation therapies, which are anticipated to evolve rapidly to become the next big therapeutic approach in the coming decade. Driven by the research and development efforts, high investment activity and increased involvement of prominent players, the RNA therapeutics and vaccines market is anticipated to witness significant growth in the foreseen future.

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY INSIGHTS

The report delves into the current state of the RNA therapeutics and RNA vaccines market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications.

2. 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio.

3. Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines.

4. Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell.

5. Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations.

6. Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field.

7. Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases.

8. Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 Billion across various funding rounds in the past four years.

9. The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years.

10. The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of more than 50% between 2026 to 2035.

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY SEGMENTS

Vaccines Account for the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the type of modality, the market is segmented into RNA therapeutics and RNA vaccines. At present, RNA vaccines capture a substantial proportion of the RNA therapeutics and RNA vaccines market. This trend is unlikely to change in the near future.

repRNA Dominates the RNA Therapeutics and RNA Vaccines Market During the Forecast Period

Based on the type of molecule, the market is segmented into replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA. At present, replicating RNA holds the maximum share of the the RNA therapeutics and RNA vaccines market. However, self amplifying RNA is likely to drive the market in the near future.

Infectious Diseases Segment Captures the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the therapeutic area, the market is segmented into infectious diseases and oncological disorders. Currently, infectious diseases account for the 100% share of the RNA therapeutics and RNA vaccines market. However, oncological disorders segment is likely to drive the market in the near future.

Intradermal Route Occupies for the Largest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the route of administration, the market is segmented into intradermal, intramuscular and intravenous. Currently, the intradermal route holds the majority share of the RNA therapeutics and RNA vaccines market. However, the intramuscular route is likely to drive the market in the near future.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Asia-Pacific. The majority of the share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in North America is expected to grow at a higher CAGR.

Example Players in the RNA Therapeutics and RNA Vaccines Market

• Alphavax
• Arcturus Therapeutics
• Atyr Pharma
• Gritstone Bio
• HDT Bio
• MiNA Therapeutics
• VLP Therapeutics

RNA THERAPEUTICS AND RNA VACCINES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the RNA therapeutics and RNA vaccines market, focusing on key market segments, including [A] type of modality, [B] type of molecule, [C] therapeutic areas, [D] route of administration [E] and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of modality, [B] type of molecule, [C] type of delivery vehicle, [D] phase of development [E] therapeutic area and [F] key niche market segments (circRNA and saRNA). Additionally, the chapter includes analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players (in terms of number of therapies).
• Technology Landscape: A comprehensive evaluation of technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, considering various parameters, such as [A] class of molecule, [B] type of molecule, [C] capabilities of the technology, [D] therapeutic area and [E] highest phase of development. Additionally, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their [F] year of establishment, [G] company size, [H] location of headquarters and [I] operational model.
• Drug Profiles: In-depth profiles of drug candidates that are in advanced stages of development, focusing on [A] details on its developer, [B] drug overview, [C] clinical trial information, [D] clinical trial endpoints, [E] clinical trial results and [F] estimated sales.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various next generation RNA therapeutics and RNA vaccines, based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] type of sponsor, [F] therapeutic area, [G] study design, [H] leading organizations (in terms of number of trials), [I] focus area and [J] geography.
• Patent Analysis: Detailed analysis of various patents filed / granted related to next generation RNA therapeutics and RNA vaccines based on [A] type of patent (granted patents, patent applications and others), [B] patent publication year, [C] patent jurisdiction, [D] CPC symbols, [E] emerging focus areas, [F] patent age, [G] leading industry / non-industry players (in terms of number of patents filed / granted) and [H] patent valuation.

Partnerships and Collaborations: An analysis of partnerships established in this sector based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] focus of partnership, [E] purpose of partnership, [F] therapeutic area, [G] most active players (in terms of number of partnerships) and [H] the regional distribution of partnership activity in this market.

• Funding and Investment Analysis: A detailed evaluation of the investments made in this domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] type of molecule, [D] amount invested, [E] geography, [F] purpose of funding, [G] stage of development, [H] therapeutic area, [I] most active players (in terms of number and amount of funding instances) and [J] leading investors (in terms of number of funding instances).
• Big Pharma Analysis: A comprehensive examination of various initiatives focused on next generation RNA therapeutics and RNA vaccines undertaken by major pharmaceutical companies based on several relevant parameters, such as [A] number of initiatives, [B] year of initiative, [C] type of initiative, [D] purpose of initiative, [E] focus of initiative and [F] location of headquarters.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. RNA Therapeutics and RNA Vaccines Market Overview
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
• 5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
• 5.3. Types of Next Generation RNA Molecules
• 5.4. Key Aspects of Next Generation RNA Molecules
• 5.5. Key Challenges Associated with Traditional RNA Modalities
• 5.6. Advantages of Using Next Generation RNA Modalities

6. MARKET LANDSCAPE

• 6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
  • 6.1.1. Analysis by Type of Modality
  • 6.1.2. Analysis by Type of Molecule
  • 6.1.3. Analysis by Delivery Vehicle
  • 6.1.4. Analysis by Phase of Development
  • 6.1.5. Analysis by Therapeutic Area
  • 6.1.6. Most Active Players: Analysis by Number of Therapies
• 6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
  • 6.2.1. Analysis by Phase of Development
  • 6.2.2. Analysis by Route of Administration
  • 6.2.3. Analysis by Therapeutic Area
• 6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
  • 6.3.1. Analysis by Year of Establishment
  • 6.3.2. Analysis by Company Size
  • 6.3.3. Analysis by Location of Headquarters
• 6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
  • 6.4.1. Analysis by Phase of Development
  • 6.4.2. Analysis by Therapeutic Area
  • 6.4.3. Most Active Players: Analysis by Number of Therapies
• 6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
  • 6.5.1. Analysis by Phase of Development
  • 6.5.2. Analysis by Therapeutic Area
  • 6.5.3. Most Active Players: Analysis by Number of Therapies

7. TECHNOLOGY LANDSCAPE

• 7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
  • 7.1.1. Analysis by Class of Molecule
  • 7.1.2. Analysis by Type of Molecule
  • 7.1.3. Analysis by Capabilities of the Technology
  • 7.1.4. Analysis by Therapeutic Area
  • 7.1.5. Analysis by Highest Phase of Development
• 7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Operational Model

8. DRUG PROFILES

• 8.1. Gemcovac
  • 8.1.1. Developer Overview
  • 8.1.2. Drug Overview
  • 8.1.3. Clinical Trial Information
  • 8.1.4. Clinical Trial Endpoints
  • 8.1.5. Clinical Trial Results
  • 8.1.6. Estimated Sales
• 8.2. ATYR1923
  • 8.2.1. Developer Overview
  • 8.2.2. Drug Overview
  • 8.2.3. Clinical Trial Information
  • 8.2.4. Clinical Trial Endpoints
  • 8.2.5. Clinical Trial Results
  • 8.2.6. Estimated Sales
• 8.3. ARCT-154
  • 8.3.1. Developer Overview
  • 8.3.2. Drug Overview
  • 8.3.3. Clinical Trial Information
  • 8.3.4. Clinical Trial Endpoints
  • 8.3.5. Clinical Trial Results
  • 8.3.6. Estimated Sales
• 8.4. GRT-C901
  • 8.4.1. Developer Overview
  • 8.4.2. Drug Overview
  • 8.4.3. Clinical Trial Information
  • 8.4.4. Clinical Trial Endpoints
  • 8.4.5. Clinical Trial Results
  • 8.4.6. Estimated Sales
• 8.5. VLPCOV-01
  • 8.5.1. Developer Overview
  • 8.5.2. Drug Overview
  • 8.5.3. Estimated Sales
• 8.6. AVX901
  • 8.6.1. Developer Overview
  • 8.6.2. Drug Overview
  • 8.6.3. Clinical Trial Information
  • 8.6.4. Clinical Trial Endpoints
  • 8.6.5. Clinical Trial Results
  • 8.6.6. Estimated Sales
• 8.7. MTL-CEBPA + Sorafenib
  • 8.7.1. Developer Overview
  • 8.7.2. Drug Overview
  • 8.7.3. Clinical Trial Information
  • 8.7.4. Clinical Trial Endpoints
  • 8.7.5. Clinical Trial Results
  • 8.7.6. Estimated Sales
• 8.8. SLATE
  • 8.8.1. Developer Overview
  • 8.8.2. Drug Overview
  • 8.8.3. Clinical Trial Information
  • 8.8.4. Clinical Trial Endpoints
  • 8.8.5. Clinical Trial Results
  • 8.8.6. Estimated Sales

9. CLINICAL TRIAL ANALYSIS

• 9.1. Analysis Methodology and Key Parameters
• 9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
  • 9.2.1. Analysis by Trial Registration Year
  • 9.2.2. Analysis by Trial Status
  • 9.2.3. Analysis by Trial Registration Year and Trial Status
  • 9.2.4. Analysis by Trial Phase
  • 9.2.5. Analysis by Patients Enrolled
  • 9.2.6. Analysis by Type of Sponsor
  • 9.2.7. Analysis by Therapeutic Area
  • 9.2.8. Analysis by Study Design
  • 9.2.9. Leading Organizations: Analysis by Number of Trials
  • 9.2.10. Analysis by Focus Area
  • 9.2.11. Analysis by Geography

10. PATENT ANALYSIS

• 10.1. Analysis Methodology and Key Parameters
• 10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
  • 10.2.1. Analysis by Type of Patent
  • 10.2.2. Analysis by Patent Publication Year
  • 10.2.3. Analysis by Patent Jurisdiction
    • 10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
    • 10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
    • 10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
  • 10.2.4. Analysis by CPC Symbols
  • 10.2.5. World Cloud Analysis: Emerging Focus Areas
  • 10.2.6. Analysis by Patent Age
  • 10.2.7. Leading Industry Players: Analysis by Number of Patents
  • 10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
• 10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
• 10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis

11. PARTNERSHIPS AND COLLABORATIONS

• 11.1. Partnership Models
• 11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
  • 11.2.1. Analysis by Year of Partnership
  • 11.2.2. Analysis by Type of Partnership
  • 11.2.3. Analysis by Year and Type of Partnership
  • 11.2.4. Analysis by Year and Type of Molecule
  • 11.2.5. Analysis by Focus of Partnership
  • 11.2.6. Analysis by Purpose of Partnership
  • 11.2.7. Analysis by Therapeutic Area
  • 11.2.8. Most Active Players: Analysis by Number of Partnerships
  • 11.2.9. Analysis by Geography
    • 11.2.9.1. Local and International Agreements
    • 11.2.9.2. Intracontinental and Intercontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS

• 12.1. Types of Funding
• 12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
• 12.3. Analysis by Year of Funding
• 12.4. Analysis by Type of Funding
• 12.5. Analysis by Type of Molecule
• 12.6. Analysis of Amount Invested by Year of Funding
• 12.7. Analysis of Amount Invested by Type of Funding
• 12.8. Analysis by Geography
• 12.9. Analysis by Year and Type of Funding
• 12.10. Analysis by Purpose of Funding
• 12.11. Analysis by Stage of Development
• 12.12. Analysis by Therapeutic Area
• 12.13. Most Active Players: Analysis by Number of Funding Instances
• 12.14. Most Active Players: Analysis by Amount Invested
• 12.15. Leading Investors: Analysis by Number of Funding Instances

13. BIG PHARMA INITIATIVES

• 13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
  • 13.1.1. Analysis by Number of Initiatives
  • 13.1.2. Analysis by Year of Initiative
  • 13.1.3. Analysis by Type of Initiative
    • 13.1.3.1. Analysis by Type of Partnership
    • 13.1.3.2. Analysis by Type of Funding
  • 13.1.4. Analysis by Purpose of Initiative
  • 13.1.5. Analysis by Year and Number of Initiatives
  • 13.1.6. Analysis by Focus of Initiative
  • 13.1.7. Analysis by Location of Headquarters of Big Pharma Players

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, till 2035

• 14.1. Key Assumptions and Methodology
• 14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (till 2035)
  • 14.2.1. Scenario Analysis
• 14.3. Key Market Segmentations
• 14.4. Dynamic Dashboard

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

• 15.1. Therapeutics: Forecasted Estimates (till 2035)
• 15.2. Vaccines: Forecasted Estimates (till 2035)
• 15.3. Data Triangulation and Validation

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

• 16.1. repRNA: Forecasted Estimates (till 2035)
• 16.2. saRNA: Forecasted Estimates (till 2035)
• 16.3. sacRNA: Forecasted Estimates (till 2035)
• 16.4. sa-mRNA: Forecasted Estimates (till 2035)
• 16.5. tRNA: Forecasted Estimates (till 2035)
• 16.6. Data Triangulation and Validation

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

• 17.1. Infectious Diseases: Forecasted Estimates (till 2035)
• 17.2. Oncological Disorders: Forecasted Estimates (till 2035)
• 17.3. Pulmonary Disorders: Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

• 18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (till 2035)
• 18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (till 2035)
• 18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

• 19.1. North America: Forecasted Estimates (till 2035)
  • 19.1.1. US: Forecasted Estimates (till 2035)
• 19.2. Europe: Forecasted Estimates (till 2035)
  • 19.2.1. France: Forecasted Estimates (till 2035)
  • 19.2.2. Italy: Forecasted Estimates (till 2035)
  • 19.2.3. Spain: Forecasted Estimates (till 2035)
  • 19.2.4. UK: Forecasted Estimates (till 2035)
  • 19.2.5. The Netherlands: Forecasted Estimates (till 2035)
• 19.3. Asia-Pacific: Forecasted Estimates (till 2035)
  • 19.3.1. India: Forecasted Estimates (till 2035)
  • 19.3.2. Japan: Forecasted Estimates (till 2035)
  • 19.3.3. Singapore: Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

• 20.1. Company A
• 20.2. Company B
• 20.3. Company C
• 20.4. Company D
• 20.5. Company E

21. CONCLUSION

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료